Índice

• Editorial

  • ·Gerontology and geriatrics, a worldwide expansion in 2009: Data from the IAGG World Meeting Paris 2009, July 5–9^th

    Página :292

    B. Vellas, B. Forette

    

• JNHA: Nutrition

  • ·Metabolic response to a ketogenic breakfast in the healthy elderly

    Página :293-298

    E. Freemantle, M. Vandal, J. Tremblay-Mercier, M. Plourde, J. Poirier, S.C. Cunnane

    Resumen Resumen Esquema Esquema  

• Impact of Food Aid on Food Variety and Dietary Diversity

  • ·Impact of food aid on food variety and dietary diversity of an elderly community in Sharpeville, South Africa

    Página :300-308

    W.H. Oldewage-Theron, R. Kruger

    Resumen Resumen Esquema Esquema

• Awareness of Weight and Height

  • ·Unawareness of weight and height - the effect on self-reported prevalence of overweight in a population-based study

    Página :310-314

    E. Ramos, C. Lopes, A. Oliveira, H. Barros

    Resumen Resumen Esquema Esquema

• JNHA: Clinical Neurosciences

  • ·The association of thyroid stimulating hormone levels with cognitive function and depressed mood: The Rancho Bernardo study

    Página :317-321

    D. Kritz-Silverstein, S.T. Schultz, L.A. Palinkas, D.L. Wingard, E. Barrett-Connor

    Resumen Resumen Esquema Esquema

• Sleep Disorders and Their Impacts on Healthy, Dependent, and Frail Older Adults

  • ·Sleep disorders and their impacts on healthy, dependent, and frail older adults

    Página :322-329

    Valérie Cochen, C. Arbus, M.E. Soto, H. Villars, M. Tiberge, T. Montemayor, C. Hein, M.F. Veccherini, S. -H. Onen, I. Ghorayeb, M. Verny, L.J. Fitten, J. Savage, Y. Dauvilliers, B. Vellas

    Resumen Resumen Esquema Esquema  

• Editorial

  • ·Use of biomarkers in Alzheimer's trials

    Página :331

    B. Vellas

    
  • ·Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease

    Página :332-333

    M.W. Weiner

    

• Biomarkers for Alzheimer's Disease Trials — Biomarkers for What? A Discussion Paper

  • ·Biomarkers for Alzheimer's disease trials — biomarkers for what? A discussion paper

    Página :334-336

    S. Lovestone, M. Thambisetty

    Esquema Esquema  

• JNHA: Clinical Trials and Aging

  • ·Interpreting biomarker data in therapeutic trials

    Página :337-338

    P.S. Aisen

    Esquema Esquema
  • ·Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?

    Página :339-340

    C. Sampaio

    Resumen Resumen Esquema Esquema
  • ·How can we recognize “disease modification” effects?

    Página :341-343

    E.R. Siemers

    Esquema Esquema

• Use of Biomarkers to Select the Target Population for Clinical Trials

  • ·Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment

    Página :344-345

    P.J. Visser

    Esquema Esquema

• Molecular Imaging Markers in Clinical Trials in Alzheimer's Disease

  • ·Molecular imaging markers in clinical trials in Alzheimer's disease

    Página :346-347

    A. Nordberg

    Esquema Esquema  

• Neuro-Imaging: Structural and Functional Imaging

  • ·Neuro-imaging: Structural and functional imaging

    Página :348-349

    G.B. Frisoni

    Esquema Esquema  

• Structural Imaging Markers for Therapeutic Trials in Alzheimer's Disease

  • ·Structural imaging markers for therapeutic trials in Alzheimer's disease

    Página :350-352

    N.C. Fox, J. Kennedy

    Esquema Esquema

• JNHA: Clinical Trials and Aging

  • ·Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data

    Página :353-355

    W.M. Van Der Flier, P. Scheltens

    Esquema Esquema

• Interest of the New Criteria for Drug Trials in AD

  • ·Interest of the new criteria for drug trials in AD

    Página :356-357

    B. Dubois

    

• Use of CSF Biomarkers in Alzheimer's Disease Clinical Trials

  • ·Use of CSF biomarkers in Alzheimer's disease clinical trials

    Página :358-361

    K. Blennow, H. Zetterberg

    Esquema Esquema

• What We Have Learned from the Myriad Trials

  • ·What we have learned from the myriad trials

    Página :362-364

    S.B. Hendrix, G.K. Wilcock

    Esquema Esquema  

• JNHA: Clinical Trials and Aging

  • ·What we have learned from the xaliproden Sanofi-aventis trials

    Página :365-366

    P. Douillet, J. -M. Orgogozo

    Esquema Esquema
  • ·Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy

    Página :367-369

    C. Wischik, R. Staff

    Esquema Esquema  

• The Alzhemed™ (Tramiprosate) Experience

  • ·Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: The Alzhemedtm (Tramiprosate) experience

    Página :370-372

    D. Saumier, P.S. Aisen, S. Gauthier, B. Vellas, S.H. Ferris, A. Duong, J. Suhy, J. Oh, W. Lau, D. Garceau, D. Haine, J. Sampalis

    Esquema Esquema

• JNHA: Clinical Trials and Aging

  • ·Enrichment of MCI and early Alzheimer's disease treatment trials using neurochemical & imaging candidate biomarkers

    Página :373-375

    H. Hampel, K. Broich

    Resumen Resumen Esquema Esquema  

• The Validity of Biomarkers as Surrogate Endpoints in Alzheimer's Disease

  • ·The validity of biomarkers as surrogate endpoints in Alzheimer's disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES)

    Página :376-387

    C. C. Gispen-De Wied, M. Kritsidima, A.J.A. Elferink

    Resumen Resumen Esquema Esquema

• JNHA: Geriatric Science

  • ·Defining frailty — the holy grail of geriatric medicine

    Página :389

    S. Conroy

    

• Frailty: Defining and Measuring of a Concept

  • ·Frailty: Defining and measuring of a concept

    Página :390-394

    R.E. Pel-Littel, M.J. Schuurmans, M.H. Emmelot-Vonk, H.J.J. Verhaar

    Resumen Resumen Esquema Esquema